AIM: To evaluate whether venlafaxine-extended release (VEN-XR) is an effective treatment for cannabis dependence with concurrent depressive disorders. DESIGN: This was a randomized, 12-week, double-blind, placebo-controlled trial of out-patients (n = 103) with DSM-IV cannabis dependence and major depressive disorder or dysthymia. Participants received up to 375 mg VEN-XR on a fixed-flexible schedule or placebo. All patients received weekly individual cognitive-behavioral psychotherapy that primarily targeted marijuana use. SETTINGS: The trial was conducted at two university research centers in the United States. PARTICIPANTS: One hundred and three cannabis-dependent adults participated in the trial. MEASUREMENTS: The primary outcome measures were (i) abstinence from marijuana defined as at least two consecutive urine-confirmed abstinent weeks and (ii) improvement in depressive symptoms based on the Hamilton Depression Rating Scale. FINDINGS: The proportion of patients achieving a clinically significant mood improvement (50% decrease in Hamilton Depression score from baseline) was high and did not differ between groups receiving VEN-XR (63%) and placebo (69%) (χ1 (2) = 0.48, P = 0.49). The proportion of patients achieving abstinence was low overall, but was significantly worse on VEN-XR (11.8%) compared to placebo (36.5%) (χ1 (2) = 7.46, P < 0.01; odds ratio = 4.51, 95% confidence interval: 1.53, 13.3). Mood improvement was associated with reduction in marijuana use in the placebo group (F1,179 = 30.49, P < 0.01), but not the VEN-XR group (F1,186 = 0.02, P = 0.89). CONCLUSIONS: For depressed, cannabis-dependent patients, venlafaxine-extended release does not appear to be effective at reducing depression and may lead to an increase in cannabis use.
RCT Entities:
AIM: To evaluate whether venlafaxine-extended release (VEN-XR) is an effective treatment for cannabis dependence with concurrent depressive disorders. DESIGN: This was a randomized, 12-week, double-blind, placebo-controlled trial of out-patients (n = 103) with DSM-IV cannabis dependence and major depressive disorder or dysthymia. Participants received up to 375 mg VEN-XR on a fixed-flexible schedule or placebo. All patients received weekly individual cognitive-behavioral psychotherapy that primarily targeted marijuana use. SETTINGS: The trial was conducted at two university research centers in the United States. PARTICIPANTS: One hundred and three cannabis-dependent adults participated in the trial. MEASUREMENTS: The primary outcome measures were (i) abstinence from marijuana defined as at least two consecutive urine-confirmed abstinent weeks and (ii) improvement in depressive symptoms based on the Hamilton Depression Rating Scale. FINDINGS: The proportion of patients achieving a clinically significant mood improvement (50% decrease in Hamilton Depression score from baseline) was high and did not differ between groups receiving VEN-XR (63%) and placebo (69%) (χ1 (2) = 0.48, P = 0.49). The proportion of patients achieving abstinence was low overall, but was significantly worse on VEN-XR (11.8%) compared to placebo (36.5%) (χ1 (2) = 7.46, P < 0.01; odds ratio = 4.51, 95% confidence interval: 1.53, 13.3). Mood improvement was associated with reduction in marijuana use in the placebo group (F1,179 = 30.49, P < 0.01), but not the VEN-XR group (F1,186 = 0.02, P = 0.89). CONCLUSIONS: For depressed, cannabis-dependent patients, venlafaxine-extended release does not appear to be effective at reducing depression and may lead to an increase in cannabis use.
Authors: Michael Dennis; Susan H Godley; Guy Diamond; Frank M Tims; Thomas Babor; Jean Donaldson; Howard Liddle; Janet C Titus; Yifrah Kaminer; Charles Webb; Nancy Hamilton; Rod Funk Journal: J Subst Abuse Treat Date: 2004-10
Authors: Dustin C Lee; Nicolas J Schlienz; Erica N Peters; Robert H Dworkin; Dennis C Turk; Eric C Strain; Ryan Vandrey Journal: Drug Alcohol Depend Date: 2018-11-15 Impact factor: 4.492
Authors: Robert Miranda; Hayley Treloar; Alexander Blanchard; Alicia Justus; Peter M Monti; Thomas Chun; Robert Swift; Jennifer W Tidey; Chad J Gwaltney Journal: Addict Biol Date: 2016-01-11 Impact factor: 4.280
Authors: Frances R Levin; John J Mariani; Martina Pavlicova; Daniel Brooks; Andrew Glass; Amy Mahony; Edward V Nunes; Adam Bisaga; Elias Dakwar; Kenneth M Carpenter; Maria A Sullivan; Jean C Choi Journal: Drug Alcohol Depend Date: 2015-11-27 Impact factor: 4.492
Authors: Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese Killeen; Karen J Hartwell; Susan J Simonian Journal: Am J Addict Date: 2015-12-20